Skip to main content

Advertisement

Log in

Changes of serum levels of MMP-3, sRANKL, and OPG in juvenile-onset ankylosing spondylitis patients carrying different HLA-B27 subtypes

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Ankylosing spondylitis (AS) patients whose symptom onset occurs before 16 years of age are termed juvenile-onset ankylosing spondylitis (JAS). Investigations suggested that JAS had worse functional outcome, and abnormality of bone metabolism can appear in early stage of AS. The objectives of this study are to compare changes of serum inflammatory and bone metabolic markers and to explore the relationship between these biomarkers and disease activity in JAS with different HLA-B27 subtypes. Serum matrix metallopeptidase-3 (MMP-3), soluble receptor activator of nuclear factor-κB ligand (sRANKL), and osteoprotegerin (OPG) were detected by ELISA in 56, 62, and 68 JAS patients, respectively, and 32 healthy individuals were as controls. Serum MMP-3 and sRANKL were significantly higher and OPG in JAS was slightly higher than those in controls. There was no significant difference in the level of MMP-3, sRANKL, and OPG among JAS patients with B27 negativity, B*2704, B*2705, and B*2715, respectively. Serum levels of MMP-3 showed positive correlation with BASDAI and BASFI (Bath Ankylosing Spondylitis Disease Activity Index and Functional Index). Serum level of sRANKL showed positive correlation with MMP-3 and negative correlation with disease duration. The significantly higher sRANKL expression suggested the enhanced osteoclast function and imbalance of RANKL/OPG system in the inflammatory process of JAS patients carrying different B27 subtypes. It should be paid attention to the abnormality of bone metabolism during the treatment of JAS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Shi GY (1999) Early clinical characteristic of juvenile-onset spondyloarthropathies. Chin J Rheumatol 3(3):131–132

    Google Scholar 

  2. Lin YC, Liang TH, Chen WS et al (2009) Differences between juvenile-onset ankylosing spondylitis and adult-onset ankylosing spondylitis. J Chin Med Assoc 72(22):573–580

    Article  PubMed  Google Scholar 

  3. Stone M, Warren RW, Bruckel J et al (2005) Juvenile-onset ankylosing spondylitis is associated with worse functional outcomes than adult-onset ankylosing spondylitis. Arthritis Rheum 53(3):445–451

    Article  PubMed  Google Scholar 

  4. van der Weijden MA, van Denderen JC, Lems WF et al (2011) Low bone mineral density is related to male gender and decreased functional capacity in early spondylarthropathies. Clin Rheumatol 30(4):497–503

    Article  PubMed Central  PubMed  Google Scholar 

  5. Bao J, Chen Y, Bao YX (2014) Prevalence and risk factors of low bone mineral density in juvenile onset ankylosing spondylitis. Calcif Tissue Int 95(2):108–111

    Article  CAS  PubMed  Google Scholar 

  6. Chen CH, Lin KC, Yu DT et al (2006) Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology 45:414–420

    Article  CAS  PubMed  Google Scholar 

  7. Viswanath V, Myles A, Dayal R et al (2011) Levels of serum matrix metalloproteinase-3 correlate with disease activity in the enthesitis-related arthritis category of juvenile idiopathic arthritis. J Rheumatol 38(11):2482–2487

    Article  CAS  PubMed  Google Scholar 

  8. Maksymowych WP, Landewé R, Conner-Spady B et al (2007) Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 56(6):1846–1853

    Article  CAS  PubMed  Google Scholar 

  9. Vandooren B, Kruithof E, Yu DT et al (2004) Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 50(9):2942–2953

    Article  CAS  PubMed  Google Scholar 

  10. Sarma PK, Misra R, Aggarwal A (2008) Elevated serum receptor activator of NF kappaB ligand (RANKL), osteoprotegerin (OPG), matrix metalloproteinase (MMP)3, and ProMMP1 in patients with juvenile idiopathic arthritis. Clin Rheumatol 27(3):289–294

    Article  PubMed  Google Scholar 

  11. Thor U, Arne Y, Øie E et al (2005) Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 111:2461–2468

    Article  Google Scholar 

  12. Sato K, Takayanagi H (2006) Osteoclasts, rheumatoid arthritis, and osteoimmunology. Curr Opin Rheumatol 18:419–426

    Article  CAS  PubMed  Google Scholar 

  13. Boyce BF, Schwarz EM, Xing LP (2006) Osteoclast precursors: cytokine-stimulated immunomodulators of inflammatory bone disease. CurrOpin Rheumatol 18:427–432

    CAS  Google Scholar 

  14. Lone J, John-Bjarne H, Jan B et al (2011) Serum osteoprotegerin levels are related to height loss: the Tromsø Study. Eur J Epidemiol 26:305–312

    Article  Google Scholar 

  15. Crotti TN, Smith MD, Weedon H et al (2002) Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 61:1047–1054

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Haynes DR, Barg E, Crotti TN et al (2003) Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology 42:123–134

    Article  CAS  PubMed  Google Scholar 

  17. Wendling D (2005) Bone loss in AS: can we put the puzzle together? J Rheumatol 32:1184–1185

    PubMed  Google Scholar 

  18. Lems W (2007) Clinical relevance of vertebral fractures: why are vertebral fractures so often overlooked? Ann Rheum Dis 66:2–4

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Mou Y, Wu Z, Gu J, Liao Z et al (2010) HLA-B27 polymorphism in patients with juvenile and adult-onset ankylosing spondylitis in Southern China. Tissue Antigens 75:56–60

    Article  CAS  PubMed  Google Scholar 

  20. Jie-ruo GU, Han-wei ZHANF, Li-ke ZHAO et al (2004) The significance of matrix metalloproteinase-3 response down-regulation in the treatment of ankylosing spondylitis by anti-TNF-a monoclonal antibody remicade. Chin Rem Clin 4(4):270–276

    Google Scholar 

  21. Viswanath V, Myles A, Dayal R et al (2011) Levels of serum matrix metalloproteinase-3 correlate with disease activity in the enthesitis-related arthritis category of juvenile idiopathic arthritis. J Rheumatol 38(11):2482–2487

    Article  CAS  PubMed  Google Scholar 

  22. Takayanagi H, Iizuka H, Juji T et al (2000) Involvement of receptor activator of nuclear factorκB ligand osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 43:259–269

    Article  CAS  PubMed  Google Scholar 

  23. Dayer JM, Bresnihan B (2002) Targeting interleukin 1 in the treatment of rheumatoid arthritis. Arthritis Rheum 46:574–578

    Article  CAS  PubMed  Google Scholar 

  24. Takayanagi H (2005) Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med 83(3):170–179

    Article  CAS  PubMed  Google Scholar 

  25. Ta HM, Nguyen GT, Jin HM et al (2010) Structure-based development of a receptor activator of nuclear factor-kappaB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis. Proc Natl Acad Sci U S A 107(47):20281–20286

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Grazio S, Kusić Z, Cvijetić S et al (2012) Relationship of bone mineral density with disease activity and functional ability in patients with ankylosing spondylitis: a cross-sectional study. Rheumatol Int 32(9):2801–2808

    Article  CAS  PubMed  Google Scholar 

  27. Van der Weijden MA, van Denderen JC, Lems WF et al (2011) Low bone mineral density is related to male gender and decreased functional capacity in early spondylarthropathies. Clin Rheumatol 30(4):497–503

    Article  PubMed Central  PubMed  Google Scholar 

  28. Arends S, Spoorenberg A, Bruyn GA et al (2011) The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: a cross-sectional analysis. Osteoporos Int 22(5):1431–1439

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Franck H, Meurer T, Hofbauer LC (2004) Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheumatol 31(11):2236–2241

    CAS  PubMed  Google Scholar 

  30. Kim HR, Lee SH, Kim HY (2006) Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). Rheumatology 45:1197–1200

    Article  CAS  PubMed  Google Scholar 

  31. Téletchéa S, Stresing V, Hervouet S et al (2014) Novel RANK antagonists for the treatment of bone-resorptive disease: theoretical predictions and experimental validation. J Bone Miner Res 29(6):1466–77

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the 5010 Subject of Sun Yat-sen University (2007023) and National Natural Science Foundation of China Grant (31070806).

Disclosure

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jie-Ruo Gu.

Additional information

Yi-Kun Mou and Ping-Ping Zhang contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mou, YK., Zhang, PP., Li, QX. et al. Changes of serum levels of MMP-3, sRANKL, and OPG in juvenile-onset ankylosing spondylitis patients carrying different HLA-B27 subtypes. Clin Rheumatol 34, 1085–1089 (2015). https://doi.org/10.1007/s10067-015-2940-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-015-2940-z

Keywords

Navigation